SCHEMBL23489015

SCHEMBL23489015

CCCOc1cc(C(=O)O)c(N)cc1OC

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.53
LCK P06239 1/20 0.46
FYN P06241 1/20 0.46
TP53 P04637 2/20 0.46
DPP4 P27487 1/20 0.44
ALDH1A1 P00352 3/20 0.44
MAPT P10636 3/20 0.43
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
HSD17B10 Q99714 3/20 0.43
TSHR P16473 2/20 0.43
MAPK1 P28482 1/20 0.43
HPGD P15428 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
HMGCR P04035 1/20 0.41
USP2 O75604 1/20 0.41
POLB P06746 1/20 0.41
GAA P10253 1/20 0.41
CASP1 P29466 1/20 0.41
HTT P42858 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13257727 0.93 KDM4E (0.51) KDM4ELCKFYNTP53ALDH1A1
SCHEMBL13299069 0.93 KDM4E (0.51) KDM4ELCKFYNTP53ALDH1A1
SCHEMBL2235600 0.91 KDM4E (0.56) KDM4ELCKFYNALDH1A1MAPT
SCHEMBL18089590 0.89 KDM4E (0.54) KDM4ELCKFYNALDH1A1MAPT
SCHEMBL29597889 0.88 KDM4E (0.53) KDM4ELCKFYNALDH1A1MAPT
SCHEMBL2330272 0.88 KDM4E (0.53) KDM4ELCKFYNALDH1A1MAPT
SCHEMBL14705178 0.87 KDM4E (0.73) KDM4EDPP4ALDH1A1MAPTKMT2A
SCHEMBL3842703 0.87 KDM4E (0.51) KDM4ELCKFYNALDH1A1MAPT
SCHEMBL4377156 0.87 KDM4E (0.51) KDM4ELCKFYNALDH1A1MAPT
SCHEMBL3324427 0.87 KDM4E (0.51) KDM4ELCKFYNALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12605353-B2 PDIA4 inhibitors and use thereof for inhibiting β-cell pathogenesis and treating diabetes ACADEMIA SINICA (TW) 2026-04-21 US disclosed
EP-4069252-B1 PDIA4 INHIBITORS AND USE THEREOF FOR INHIBITING SS-CELL PATHOGENESIS AND TREATING DIABETES ACADEMIA SINICA (CN) 2025-12-10 EP disclosed
CN-114761025-B PDIA4 inhibitors and their use for inhibiting beta cell pathologies and for treating diabetes 施明哲 2024-03-12 CN disclosed
US-20230046445-A1 PDIA4 INHIBITORS AND USE THEREOF FOR INHIBITING ß-CELL PATHOGENESIS AND TREATING DIABETES ACADEMIA SINICA (TW) 2023-02-16 US disclosed
US-20230046445-A1 PDIA4 INHIBITORS AND USE THEREOF FOR INHIBITING ß-CELL PATHOGENESIS AND TREATING DIABETES ACADEMIA SINICA (TW) 2023-02-16 US disclosed
CN-114761025-A PDIA4 inhibitor and application thereof in inhibiting beta cell pathology and treating diabetes 施明哲 2022-07-15 CN disclosed
WO-2021113062-A1 PDIA4 INHIBITORS AND USE THEREOF FOR INHIBITING ß-CELL PATHOGENESIS AND TREATING DIABETES ACADEMIA SINICA (CN) 2021-06-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12605353-B2 PDIA4 inhibitors and use thereof for inhibiting β-cell pathogenesis and treating diabetes PDIA4, PDIA5, PDIA6 KDM4E 2024/4885LCK 2080/4885FYN 3852/4885
US-20230046445-A1 PDIA4 INHIBITORS AND USE THEREOF FOR INHIBITING ß-CELL PATHOGENESIS AND TREATING DIABETES PDIA4, PDIA6, PDIA5 KDM4E 1437/4885LCK 2853/4885FYN 3994/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.